[Serum autoantibodies profiling and early-stage cancer detection]. - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Médecine/Sciences Année : 2011

[Serum autoantibodies profiling and early-stage cancer detection].

Autoanticorps et diagnostic précoce des cancers


It is now well established that an immune response to cancer is elicited in humans, as demonstrated in part by the identification of autoantibodies against a number of tumor-associated antigens in sera from patients with different types of cancer. During these past few years, proteomic approaches have been developed to identify tumor-associated antigens and their cognate autoantibodies. Detection of a panel of serum autoantibodies has thus been proposed as a new method for early cancer diagnosis. Early detection seems to be particularly adequate in high-risk populations, such as heavy smokers for lung cancer or in women with high mammographic density for breast cancer. In this review, we highlight the features of serum autoantibody biomarkers and outline the proteomic strategies employed to identify and validate their use in clinical practice for cancer screening and diagnosis. We particularly emphasize the clinical utility of autoantibody signatures, using the examples of lung and breast cancer. Finally, we discuss the challenges remaining for clinical validation.

Dates et versions

hal-01936190 , version 1 (27-11-2018)



Caroline Desmetz, Jérôme Lacombe, Alain Mangé, Thierry Maudelonde, Jérôme Solassol. [Serum autoantibodies profiling and early-stage cancer detection].. Médecine/Sciences, 2011, 27 (6-7), pp.633 - 638. ⟨10.1051/medsci/2011276016⟩. ⟨hal-01936190⟩
45 Consultations
0 Téléchargements



Gmail Mastodon Facebook X LinkedIn More